example, by a lower FLT3 mutation rate. 2 It remains unclear whether a diagnosis of AEL per se or the association with poor risk cytogenetic features or other poor risk characteristics causes the more adverse prognosis. 3 So far, mutations of FLT3 and NRAS 2 only have been studied in more detail in AEL. We previously suggested that the different AML and myelodysplastic syndrome (MDS) subtypes with predominant erythropoiesis may be combined into one category. 4 Others proposed that the clinical and genetic features of AML with erythroid predominance are closer to highgrade MDS than to other types of AML. 5 We investigated 14 candidate genes combined with the cytogenetic background and the prognostic impact in 92 AEL patients (31 female/61 male; median age, 68.8 years; range: 21.3-88.3 years; Supplementary Table S1). Survival data was available in 74 patients. All patients had erythroleukemia (erythroid/myeloid leukemia), 6 pure erythroid leukemia was not considered. Patients received induction and consolidation chemotherapy according to AML Cooperative Group (AMLCG) 7 or comparable protocols. Bone marrow samples were sent for diagnosis to the MLL Munich Leukemia Laboratory from August 2005 to May 2012. All patients gave their written consent for genetic analyses and research studies. Part of the patients had been included in a previous study. 4 All cases were investigated by cytomorphology, chromosome banding analysis and, in case of a normal karyotype, by array comparative genomic hybridization (CGH). Because of limitations in sample material, we combined data from 454 amplicon deep sequencing (Roche, Branford, CT, USA) 8 with Sanger sequencing and melting curve analyses (for details see Supplementary Appendix). The various screening techniques for the different genes are given in Supplementary Table S2 . Of note, despite the incongruent molecular screening programme, no significant bias was detectable in terms of detection of minor subclones by deep sequencing in comparison to other assays. Thus, no influence on the subsequent results is expected.
Cytomorphologic characteristics of the cohort are described in Supplementary Appendix (see also Supplementary Table S3 (Figure 1 ).
Clonality analyses were performed by estimating the mutation load by deep sequencing in cases with 41 mutation. When we analyzed ASXL1mut, which were found in coincidence with DNMT3A, RUNX1 or TP53 mutations, the mutation loads were similar for the different genes. This also holds true for other combinations of mutations ( Supplementary Figures S1A-E) . Although it has to be seen that different molecular technologies were combined, those results suggest that AEL represents a rather monoclonal disease than a composition of different clones as this was recently supposed for MDS. 10 Alternatively, AEL may have a strong hyperproliferative potential after acquisition of all clonal abnormalities thus being able to overgrow clones with fewer mutations.
Ring sideroblasts were more frequent in NPM1wt as compared with NPM1mut cases (Po0.001). The proportion of dysplastic erythropoietic cells (P ¼ 0.002) and of ring sideroblasts (P ¼ 0.034) were higher in cases with complex karyotypes than non-complex karyotypes (Supplementary Table S3 ). Therefore, a subset of AEL patients shows vicinity to MDS cases.
Only genes that were found mutated in three or more cases were included in the correlation studies. TP53mut were found in 40 of 77 (43.5%) NPM1wt cases, whereas no TP53mut was found in the 15 NPM1mut cases (Po0.001). TP53mut were found in 38 of 83 (42.2%) MLL-PTD-negative cases, whereas no TP53mut was found in 7 MLL-PTD-positive cases (P ¼ 0.020). TP53mut were only found in WT1wt and not in WT1mut cases (39/80; 44.8% vs 0/7; 0.0%; P ¼ 0.015; Figure 1 Median overall survival (OS) of the cohort was 14.3 months (median follow-up: 23.5 months). Intermediate MRC cases had a better outcome than adverse MRC 9 karyotype cases (median OS not reached (n.r.) vs 6.4 months, P ¼ 0.002; median event-free survival (EFS) n.r. vs 5.5 months, Po0.001; Supplementary Figure S2A ). OS (median n.r. vs 9.3 months; P ¼ 0.012) and EFS (25.2 vs 5.6 months; P ¼ 0.001) were better for non-complex karyotype cases. Cases with a normal karyotype showed higher (Table 1A) .
OS (
NPM1mut cases showed better outcome than NPM1wt (median OS n.r. vs 9.3 months, Po0.001; median EFS n.r. vs 6.1 months, P ¼ 0.002; Supplementary Figure S2B ). TP53mut cases had shorter OS (median 6.4 months vs n.r.; P ¼ 0.001) and EFS (median, 5.7 vs 25.2 months; P ¼ 0.001) than TP53wt (Supplementary Figure S2C) . RUNX1mut patients had shorter OS (median, 4.1 vs 19.5 months; P ¼ 0.007) and EFS (median 4.1 vs 11.7 months; P ¼ 0.030) than RUNX1wt patients; Supplementary Figure S2D) . ASXL1mut cases showed a trend of shorter OS (median 5.4 vs 19.5 months; P ¼ 0.082), whereas EFS did not differ significantly (median 5.4 vs 12.4 months; P ¼ n.s.; Supplementary Figure S2E ; Table 1B) .
When the intermediate MRC risk group was separately analyzed, the favorable prognostic impact of NPM1mut as compared with NPM1wt was confirmed (OS: P ¼ 0.013; EFS: P ¼ 0.075). RUNX1mut (OS: P ¼ 0.001; EFS: P ¼ 0.001) and ASXL1mut (OS: P ¼ 0.024; EFS: P ¼ 0.042) conferred worse outcomes. Survival of TP53mut cases was worse but statistical comparison was hampered by the limited number of TP53mut cases in this subgroup.
By univariate analysis, the following parameters were significant for OS: higher age (P ¼ 0.001, hazards ratio (HR) ¼ 1.54 per 10 years of increase), t-AEL vs de novo AEL (P ¼ 0.002, HR ¼ 4.79), adverse cytogenetic MRC risk group (P ¼ 0.003, HR ¼ 2.88), higher white blood cell (WBC) counts (P ¼ 0.031, HR ¼ 1.11 per 10 9 /l increase), and RUNX1 (P ¼ 0.012, HR ¼ 4.01) and TP53mut (P ¼ 0.001, HR ¼ 3.11), whereas NPM1mut (P ¼ 0.003, HR ¼ 0.11) were favorable (Supplementary Figure 3A) . Table S6 ).
In conclusion, we could confirm the high frequency of adverse karyotypes 9 of 48.9% in our AEL cohort. Santos et al. 3 and Hasserjian et al.
2 described adverse karyotypes in 61% and 64% of AEL patients, respectively. Unfavorable karyotypes were mostly due to the presence of complex karyotypes, which had a frequency of 40.2% in our study. Patients with intermediate karyotypes had a better outcome than patients with adverse MRC 9 karyotypes (OS: P ¼ 0.002; EFS: Po0.001). Wells et al.
1 reported a median OS of 14 months for patients with standard risk cytogenetics and 2 months for poor risk karyotypes (P ¼ 0.005) in AEL. In the study by Hasserjian et al.,
2 outcome of AEL patients was significantly influenced by the cytogenetic risk group. In contrast, the blast count had no prognostic relevance when AEL patients were compared with patients with other myeloid subtypes (AML with myelodysplasia-related changes or MDS) with erythroid hyperplasia. 2 We found a high frequency of mutations (85/92; 92.4%) in our AEL cohort. The mutation profiles differed significantly from overall AML.
11 NPM1mut were found in 16.3% and FLT3-ITD in only 3.3% of our AEL patients, thereby much lower when compared with overall AML patients that presented 430% of NPM1 12 and 20-25% of FLT3-ITD mutated cases. 13, 14 Similarly, Hasserjian et al. reported FLT3-ITD to occur in only 6% of the AEL patients. Abbreviations: EFS, event-free survival; n.r., not reached; mut, mutated; n.s., not significant; OS, overall survival; wt, wild type. Only molecular markers which were found mutated in at least five cases in which survival data was available were considered in this analysis.
Letters to the Editor
We found high frequencies of TP53mut (43.5%), and further detected DNMT3A (13.0%), ASXL1 (8.0%), MLL-PTD (7.8%), WT1 (7/ 88; 8.0%) and IDH1 (6/80; 7.5%) mutations in our AEL cohort. We could confirm the association of TP53mut with complex karyotypes 11,15 also in AEL. NPM1mut had a positive prognostic impact, whereas TP53, RUNX1 and ASXL1mut were adverse. The high rate of TP53mut contributes to explain the adverse outcome in AEL. Based on these results, therapeutic decisions in AEL patients should always consider cytogenetics and, in the future, molecular mutation profiles focusing on NPM1, RUNX1 and TP53.
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